The purpose of this project is to develop vaccines against otitis media and respiratory tract diseases caused by nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (M. cat). For NTHi, we demonstrated earlier that detoxified lipooligosaccharide (dLOS)-protein conjugates from NTHi elicited a significant rise of anti-LOS antibodies with bactericidal activity in rabbits and conferred protection against otitis media in a chinchilla model. In the past year, a clinical batch of vaccine was produced and met all the requirements of safety and immunogenicity issued by Food and Drug Administration (FDA). As an investigational new drug (IND), this vaccine was approved by FDA to be used in humans. Currently, a Phase I clinical trial is conducted by NIDCDs scientists. The preliminary results indicate that the vaccine is safe and able to generate specific antibodies against NTHi pathogen or M. cat., we demonstrated that detoxified lipooligosaccharide (dLOS)-protein conjugate vaccines from M. cat. elicited a significant rise of anti-LOS antibodies with bactericidal activity in animal models. In addition, immunization with these conjugate vaccines conferred protection against M. cat. infection in an aerosol challenge mouse model. - Nontypeable Haemophilus influenzae, Moraxella catarrhalis, Lipooligosaccharide, Conjugate vaccine, Otitis media, Clinical trial - Human Subjects

National Institute of Health (NIH)
National Institute on Deafness and Other Communication Disorders (NIDCD)
Intramural Research (Z01)
Project #
Application #
Study Section
Special Emphasis Panel (LI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Institute on Deafness and Other Communication Disorders
United States
Zip Code
von Bartheld, Christopher S; Giannessi, Francesco (2011) The paratympanic organ: a barometer and altimeter in the middle ear of birds? J Exp Zool B Mol Dev Evol 316:402-8
Gao, Song; Peng, Daxin; Zhang, Wenhong et al. (2008) Identification of two late acyltransferase genes responsible for lipid A biosynthesis in Moraxella catarrhalis. FEBS J 275:5201-14
Yu, Shengqing; Xie, Hang; Datta, Anup et al. (2008) Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination. Infect Immun 76:4251-8
Peng, Daxin; Hu, Wei-Gang; Choudhury, Biswa P et al. (2007) Role of different moieties from the lipooligosaccharide molecule in biological activities of the Moraxella catarrhalis outer membrane. FEBS J 274:5350-9
Yu, Shengqing; Gu, Xin-Xing (2007) Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect Immun 75:2974-80
Hirano, Takashi; Jiao, Xinan; Chen, Zhong et al. (2006) Kinetics of mouse antibody and lymphocyte responses during intranasal vaccination with a lipooligosaccharide-based conjugate vaccine. Immunol Lett 107:131-9
Zhou, Qibing; Xie, Hang; Zhang, Lin et al. (2006) cis-Terpenones as an effective chemopreventive agent against aflatoxin B1-induced cytotoxicity and TCDD-induced P450 1A/B activity in HepG2 cells. Chem Res Toxicol 19:1415-9
Yu, Shengqing; Gu, Xin-Xing (2005) Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis. Infect Immun 73:2790-6
Peng, Daxin; Choudhury, Biswa P; Petralia, Ronald S et al. (2005) Roles of 3-deoxy-D-manno-2-octulosonic acid transferase from Moraxella catarrhalis in lipooligosaccharide biosynthesis and virulence. Infect Immun 73:4222-30
Hu, Wei-Gang; Berry, Julie; Chen, Jing et al. (2004) Exploration of Moraxella catarrhalis outer membrane proteins, CD and UspA, as new carriers for lipooligosaccharide-based conjugates. FEMS Immunol Med Microbiol 41:109-15

Showing the most recent 10 out of 22 publications